Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Garber

Showing results (491-500 of 605) with videos related to

Pageof 61
Sort By:
Molecular Cancer Research : MCR|September 10, 2009
Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator ClaspinJianmin Zhang, Young-Han Song, Brian W Brannigan, et al.
Journal of the National Cancer Institute|June 6, 2002
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRODavid M Euhus, Kristin C Smith, Linda Robinson, et al.
Medrxiv : the Preprint Server for Health Sciences|September 25, 2023
A cluster-randomized trial of client and provider-directed financial interventions to align incentives with appropriate case management in retail medicine outlets: results of the TESTsmART Trial in western KenyaJ Laktabai, E Kimachas, J Kipkoech, et al.
The American Journal of Gastroenterology|February 25, 2026
Colorectal neoplasia rates in Li Fraumeni SyndromeSophia R Spiegel, Caitlin Orr, Nicolas U Edgar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2026
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in <i>PALB2</i> or Somatic Mutations in <i>BRCA1</i> or <i>BRCA2</i>Nadine M Tung, Mark E Robson, Tianyu Li, et al.
Cancer|February 14, 2014
Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2Sarah A Jackson, Andrew A Davis, Jun Li, et al.
Human Mutation|June 3, 2020
Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelinesCristina Fortuno, Jessica Mester, Tina Pesaran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Progress in the management of gynecologic cancer: consensus summary statementStephen A Cannistra, Robert C Bast, Jonathan S Berek, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 24, 2022
Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-OophorectomyMeghna S Trivedi, Nadir Arber, Eitan Friedman, et al.
British Journal of Cancer|October 27, 2021
Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancerYaileen D Guzmán-Arocho, Shoshana M Rosenberg, Judy E Garber, et al.
Pageof 61

Showing results (491-500 of 605) with videos related to

Sort By:
Pageof 61
Molecular Cancer Research : MCR|September 10, 2009
Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator ClaspinJianmin Zhang, Young-Han Song, Brian W Brannigan, et al.
Journal of the National Cancer Institute|June 6, 2002
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRODavid M Euhus, Kristin C Smith, Linda Robinson, et al.
Medrxiv : the Preprint Server for Health Sciences|September 25, 2023
A cluster-randomized trial of client and provider-directed financial interventions to align incentives with appropriate case management in retail medicine outlets: results of the TESTsmART Trial in western KenyaJ Laktabai, E Kimachas, J Kipkoech, et al.
The American Journal of Gastroenterology|February 25, 2026
Colorectal neoplasia rates in Li Fraumeni SyndromeSophia R Spiegel, Caitlin Orr, Nicolas U Edgar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2026
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in <i>PALB2</i> or Somatic Mutations in <i>BRCA1</i> or <i>BRCA2</i>Nadine M Tung, Mark E Robson, Tianyu Li, et al.
Cancer|February 14, 2014
Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2Sarah A Jackson, Andrew A Davis, Jun Li, et al.
Human Mutation|June 3, 2020
Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelinesCristina Fortuno, Jessica Mester, Tina Pesaran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Progress in the management of gynecologic cancer: consensus summary statementStephen A Cannistra, Robert C Bast, Jonathan S Berek, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 24, 2022
Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-OophorectomyMeghna S Trivedi, Nadir Arber, Eitan Friedman, et al.
British Journal of Cancer|October 27, 2021
Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancerYaileen D Guzmán-Arocho, Shoshana M Rosenberg, Judy E Garber, et al.
Pageof 61